Jefferies Financial Group Inc. Makes New Investment in Eton Pharmaceuticals, Inc. $ETON

Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 34,027 shares of the company’s stock, valued at approximately $1,232,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ETON. Quarry LP purchased a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $37,000. Persistent Asset Partners Ltd purchased a new stake in shares of Eton Pharmaceuticals in the second quarter valued at $90,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter worth $44,000. Legal & General Group Plc purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at $41,000. Finally, State of Wyoming purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at $107,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ETON. Craig Hallum upped their price target on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Friday, July 17th. Finally, HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eton Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.50.

Insider Buying and Selling

In related news, insider David Krempa sold 25,000 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the transaction, the insider owned 37,025 shares of the company’s stock, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at approximately $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 125,000 shares of company stock valued at $6,204,250. Corporate insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ ETON opened at $59.78 on Monday. Eton Pharmaceuticals, Inc. has a one year low of $14.27 and a one year high of $66.37. The business’s 50-day moving average price is $45.17 and its two-hundred day moving average price is $32.02. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The company has a market capitalization of $1.71 billion, a P/E ratio of 157.32 and a beta of 0.86.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The business had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Analysts anticipate that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.